DAPTOMYCIN

Daptomycin received initial approval from the U.S. Food and Drug Administration (FDA) on 1 September 2003. It was first approved under the brand name Cubicin.

Daptomycin treats complicated skin and skin structure infections (cSSSI) and bloodstream infections caused by certain gram-positive bacteria, including vancomycin-resistant enterococcus (MRSA) and methicillin-resistant staphylococcus VRE.

Daptomycin is administered intravenously (IV) by a healthcare professional. The lyophilized powder is reconstituted with sterile water to prepare the solution for IV infusion. The recommended dosage and infusion rate vary based on the type and severity of the infection, as well as the patient's weight and kidney function. This medication is usually given once daily.

Common side effects of daptomycin include nausea, headache, diarrhea, and vomiting. Less frequently, some patients may experience muscle pain or weakness, indicating a rare condition called rhabdomyolysis. Additionally, allergic reactions to daptomycin, though uncommon, can manifest as skin rashes, itching, swelling, severe dizziness, or difficulty breathing, requiring immediate medical attention.

Daptomycin use may be associated with muscle-related side effects, including muscle pain, weakness, and, in rare cases, rhabdomyolysis. Allergic reactions, eosinophilic pneumonia, and potential interactions with statins and calcium-containing solutions have also been reported. The safety during pregnancy and breastfeeding has not been fully established. Prolonged or inappropriate use may lead to bacterial resistance. It may rarely cause a decrease in platelet counts (thrombocytopenia). Using it may increase the risk of developing Clostridium difficile-associated diarrhea, a potentially severe and life-threatening infection. Its effect on the cell membrane may lead to potential neuromuscular effects, such as tingling or numbness. This medication has been associated with rare cases of eosinophilic pneumonia, a condition characterized by an increase in certain white blood cells in the lungs.

Patients with pre-existing muscle disorders should be closely monitored, and immediate medical attention is required if severe allergic reactions or eosinophilic pneumonia symptoms occur. Patients should be monitored for neuromuscular effects and infusion-related reactions. Patients should report any concerning symptoms to their healthcare provider promptly. Regular blood counts should be performed in patients at risk for this condition. If severe diarrhea occurs during or after treatment, medical attention should be sought immediately. Patients with pre-existing neuromuscular conditions should be closely monitored during treatment. Patients who experience cough, fever, or difficulty breathing should seek medical attention promptly.

Daptomycin should be taken exactly as prescribed. Muscle-related symptoms, including pain or weakness, must be reported promptly to your doctor, particularly if you have a pre-existing muscle disorder. Signs of allergic reaction or eosinophilic pneumonia require immediate medical attention. Patients who are pregnant or breastfeeding should discuss potential risks and benefits with their doctor before commencing daptomycin. The full course must be completed as directed; premature discontinuation should be avoided. Ongoing follow-up appointments and monitoring are necessary to confirm therapeutic effectiveness and identify any adverse effects in a timely manner.

Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Protein synthesis inhibitors, and miscellaneous antibacterial agents, 12th edition, 2011, 1542 - 1543. Panpharma UK Ltd, Electronic medicines compendium (EMC), [Revised on 06 Jun 2022] [ Accessed on 22nd July 2023], https://www.medicines.org.uk/emc/product/12263/smpc#gref Merck Sharp & Dohme Corp., US Food and Drug Administration, [Revised on 04.03.2020] [Accessed on 22nd July 2023], / https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208385s00